Oncogene and Tumor Suppressor Panel 384HT Mutation PCR Array

Research Area

Browse by Pathway

Browse by Disease

Human

qBiomarker Somatic Mutation PCR Array: Human Oncogene and Tumor Suppressor Panel 384HT
The Human Oncogene and Tumor Suppressor Panel qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, comprehensive, and accurate profiling of the somatic mutation status of 36 key oncogenes and tumor suppresors of the human cancer genome. Genes covered on this panel are among the most frequently mutated in human cancers and therefore warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Oncogene and Tumor Suppressor Panel qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in all major oncogenes and tumor suppressors and has the potential for discovery and verification of drug target biomarkers for a variety of human cancers. This array includes 346 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human oncogenes and tumor suppressors. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments. Researchers with interest in in-depth mutation analysis for a specific pathway or disease are encouraged to explore relevant pathway- or disease-specific somatic mutation PCR arrays. Additional mutation assays (not included in this array) for the majority of the genes are also available.

Assay Functional Annotations

How It Works

References

Resources

Modify this Array

(Number of mutation assays for each gene follows the gene symbol)

ABL1	7
AKT1	1
ALK	2
APC	9
BRAF	12
CDKN2A	16
CSF1R	1
CTNNB1	33
EGFR	27
ERBB2	2
EZH2	3
FBXW7	4
FGFR3	8
FLT3	3
GNAQ	2
GNAS	6
HRAS	13
IDH1	5
IDH2	4
JAK2	6
KIT	32
KRAS	21
MET	3
NF2	7
NOTCH1	8
NPM1	6
NRAS	17
PDGFRA	6
PIK3CA	26
PTEN	7
RB1	2
RET	3
SRC	1
STK11	5
TP53	32
VHL	6

Assay Functional Annotations

How It Works

References

Resources

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®

Back to Top

Assay Functional Annotations

How It Works

References

Resources

The PKB/AKT pathway in cancer.Carnero A. Curr Pharm Des. 2010 Jan; 16(1):34-44
BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT, McArthur G. Cancer. 2010 Jul 13. [Epub ahead of print]
Clinical relevance of KRAS in human cancers. Jancík S, Drábek J, Radzioch D, Hajdúch M. J Biomed Biotechnol. 2010; 2010:150960.
Oncogenic Ras in tumour progression and metastasis. Giehl K. Biol Chem. 2005 Mar; 386(3):193-205
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A. 2009 Dec 1; 106(48):20411-6
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. Cell Cycle. 2009 May 1; 8(9):1352-8
Oncogenic mutations as predictive factors in colorectal cancer. Lièvre A, Blons H, Laurent-Puig P. Oncogene. 2010 May 27; 29(21):3033-43
PI(3)King Apart PTEN's Role in Cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Jul 8. [Epub ahead of print]

Back to Top